Towards single embryo transfer? Modelling clinical outcomes of potential treatment choices using multiple data sources: predictive models and patient perspectives

SA Roberts,1,* L McGowan,2 WM Hirst,1 DR Brison,3,4,5 A Vail1 and BA Lieberman3,4,5

1Health Methodology Research Group, University of Manchester, UK
2School of Nursing, Midwifery and Social Work, University of Manchester, UK
3Fetal and Maternal Health Research Group, University of Manchester, UK
4Department of Reproductive Medicine, St Mary’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
5Manchester Fertility Services, Manchester, UK

*Corresponding author

Executive summary

Health Technology Assessment 2010; Vol. 14: No. 38
DOI: 10.3310/hta14380
Executive summary

Background

In vitro fertilisation (IVF) treatments involve an egg retrieval process, fertilisation and culture of the eggs in the laboratory, and the transfer of resultant embryos back to the mother over one or more embryo replacement cycles. The first such transfer is usually of fresh embryos, while the remaining embryos may be cryopreserved for future frozen cycles. Most commonly in UK practice two embryos are transferred (double embryo transfer, DET). IVF techniques have led to a dramatic increase in the number of multiple births. Around 25% of all IVF births are twins, carrying an increased risk of maternal and infant morbidity. During the lifespan of this project the UK Human Fertilisation and Embryology Authority (HFEA) has adopted a multiple birth minimisation strategy, requiring clinics to systematically reduce the proportion of multiple births. One direct strategy to achieve this would be by increased use of single embryo transfer (SET).

Objectives

• To collate high-quality cohort data from a series of individual treatment centres to be considered alongside data collated by the HFEA for regulatory purposes.
• To develop predictive models from each of the data sources for successful live birth and twinning probabilities from fresh and frozen embryo transfers.
• To understand, through qualitative work, patients’ perspectives as they travel through the treatment process, including appropriate outcome measures, attitudes towards twins, opinions on SET and potential policies for reducing the number of twin births.
• To predict outcomes for treatment scenarios, based on proposals in the literature and developed with patients and clinicians.
• To use the modelling results to investigate with patients the acceptability of twin reduction policies within the current regulatory, funding and clinical environment.
• To consider the need for future randomised controlled trials and surveys of patient attitudes.

Methods

We adopted a multidisciplinary approach combining state-of-the-art statistical modelling with in-depth qualitative exploration of patient perspectives. The components were integrated formally through statistical modelling of scenarios proposed by patients and presentation of the modelling results to patient groups. Less formally, components were integrated through cross-disciplinary discussions within the research team. The specific components included:

• semi-structured interviews with 27 couples at various stages of IVF treatment at both UK NHS and private clinics
• collation of a UK dataset of over 90,000 patients from the HFEA registry covering the 2000–5 period
• collation of a more detailed dataset from 2000–5 of nearly 9000 patients from five diverse centres
• analysis for live birth and twin outcomes: we developed logistic regression models, including models for the implantation probability of each embryo and the receptivity of the uterus; additional models estimated effects of cryopreservation and intrapatient correlations
• use of the models to predict the outcomes of policies for selecting patients for SET or DET in the fresh cycle following egg retrieval and fertilisation; we used these predictions in simulations of treatments spanning several embryo transfer procedures
• convening two focus groups, one in the NHS and one web based on a patient organisation’s website; results of the statistical analyses were presented and potential treatment policies explored.

Results

The interviews indicate that, despite having had the risks explained, for many patients a twin birth is the ideal outcome. There was scepticism concerning the motivation to reduce twin numbers. Many equated this to saving money and a lack of due priority for fertility treatments. Potential restrictions on DET were seen to conflict with the
NHS Patient Choice agenda. Scepticism exists over the use of cryopreservation and frozen transfers.

The statistical analysis revealed no characteristics that specifically predicted multiple birth outcomes beyond those that predicted treatment success. A number of prognostic factors were confirmed and it was possible to identify some acting specifically through the embryo viability or uterine receptivity. In the fresh transfer following egg retrieval SET would lead to a reduction of approximately one-third in the live birth probability compared with DET, a result consistent with the limited data from clinical trials. Furthermore this reduction showed only weak dependence on patient characteristics.

Unless there is antagonism between embryos, it is a simply demonstrable mathematical truth that any individual woman will have a lower chance of a successful outcome in a given transfer cycle from SET compared with DET. However, from the population or clinic perspective, selection of patients based on prognostic indicators might mitigate about half of the loss in live births associated with SET in the initial fresh transfer while achieving a twin rate of 10% or less. A number of strategies based on the woman’s age and the number and quality of available embryos performed broadly similarly.

Any meaningful comparison of IVF treatments must take a complete treatment perspective, comparing success rates after use of all available frozen embryos from an egg retrieval. Our data-based simulations suggested that, if all good-quality embryos are replaced over multiple frozen embryo transfers, repeated SET has the potential to produce more live birth events than repeated DET. This would critically depend on optimising cryopreservation procedures. Universal SET could both reduce the number of twin births and lead to more couples having a child, but at an average cost of one more embryo transfer procedure per egg retrieval.

The interview and focus group data suggest that, despite the potential to maintain overall success rates, patients would prefer DET: the potential for twins is seen as positive, while additional transfer procedures are emotionally, physically and, for some, financially draining.

Conclusions

Implications for practice

1. We found significant resistance to SET and reducing twin rates, although a sizeable minority of NHS patients do accept SET. Many patients were well-informed and would challenge inaccurate or misleading information. There is a need to develop clear and accurate information if multiple birth minimisation policies are not to be perceived negatively.

2. The measure of treatment success will be crucial to the acceptance of SET. If the reporting focus continues to be the initial fresh transfer, SET can only appear disadvantageous. If the focus shifts to complete cycles, SET may match or outperform DET. However patient scepticism of cryopreservation needs to be addressed and the burden of additional transfers needs to be considered.

3. Cryopreservation then becomes crucial to maintaining success rates. This study identified scope for optimisation.

4. Selection of patients for SET may help clinics reduce the loss in fresh cycle success rates. Selection policies would be perceived as unfair by some patients limited to SET.

5. Embryo selection procedures need to be approached carefully in the context of complete treatment programmes. Processes involving invasive selection may improve fresh cycle rates at the expense of the overall cumulative live birth rate. However, there may be a role for such methods in reducing the number of cycles necessary to achieve a live birth.

6. The present UK policy of requiring clinics to reduce twin rates requires a degree of sophistication in the monitoring process. The number treated in any given centre does not allow for robust auditing or evaluation of policy changes.

7. Clinics will need reliable data to monitor and audit policy and performance. This is likely to require the development of better information systems.

Recommendations for research

1. There is an urgent need for better-quality data that permit the evaluation of complete cycles (fresh plus frozen) and link multiple treatments of the same women. Existing clinical and regulatory database systems do not in practice provide data that can robustly and directly answer the key questions. With such data our conclusions could be confirmed and analyses extended to consider interclinic differences and additional covariates.

2. Research is needed to adapt existing data monitoring tools for use in monitoring twin
rate targets and provide evaluation tools to clinics and regulators.

3. Some patient antipathy to SET may be amenable to carefully tailored and accurate information that takes account of patients’ beliefs and experiences. Surveys are needed to quantify the extent of these beliefs and develop approaches to meeting patients’ information needs.

4. Our methods could readily be extended to consider various embryo selection policies, based on either biomarkers or extended culture. As data become available, further simulation studies would be informative in determining their optimal use.

5. Ultimately, methods for optimising success rates while reducing twin rates need to be tested in properly designed randomised trials with full treatment end points. Although previous efforts to compare DET with SET in the NHS have failed to recruit, a move towards increased SET provides a unique opportunity to answer these questions.

Key messages

- For any one transfer, SET has about a one-third loss of success rate relative to DET.
- The loss can be only partially mitigated by patient and treatment cycle selection, and criteria may be criticised as unfair: all patients receiving SET will have a lower chance of success than they would with DET.
- If we consider complete cycles (fresh plus frozen transfers), it is possible for repeat SET to produce more live births than repeat DET.
- Such a strategy would require support from funders and acceptance by patients of both cryopreservation and the burden of additional transfer cycles.

Publication

How to obtain copies of this and other HTA programme reports

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).

Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue.

How to order:
– fax (with credit card details)
– post (with credit card details or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you to either print out your order or download a blank order form.

Contact details are as follows:

Synergie UK (HTA Department)                  Email: orders@hta.ac.uk
Digital House, The Lodden Centre               Tel: 0845 812 4000 – ask for ‘HTA Payment Services’
Wade Road                                      (out-of-hours answer-phone service)
Basingstoke                                    Fax: 0845 812 4001 – put ‘HTA Order’ on the fax header
Hants RG24 8QW

Payment methods

Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.

Paying by credit card
You can order using your credit card by phone, fax or post.

Subscriptions

NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40–50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

How do I get a copy of HTA on DVD?

Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.

The website also provides information about the HTA programme and lists the membership of the various committees.
The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then commissions the research by competitive tender.

Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series Health Technology Assessment.

Criteria for inclusion in the HTA journal series

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this issue of the journal was commissioned by the HTA programme as project number 05/43/01. The contractual start date was in January 2007. The draft report began editorial review in June 2009 and was accepted for publication in January 2010. As the funder, by devising a commissioning brief, the HTA programme specified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA programme or the Department of Health.

Editor-in-Chief: Professor Tom Walley CBE
Series Editors: Dr Martin Ashton-Key, Dr Aileen Clarke, Professor Chris Hyde, Dr Tom Marshall, Dr John Powell, Dr Rob Riemsma and Professor Ken Stein
Editorial Contact: edit@southampton.ac.uk